Glaxosmithkline adjuvant AS03

Ended Definitive Contract Awarded Last action

Contract number
W15QKN20C0048
Awardee
Awarding agency
Obligated
$331,536,435

Award facts

Opportunity
Contract value 99% obligated
$335,592,190.80 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Funding agency
Department of the Army Department of Defense
Set-aside
No set-aside
Competition
1 offer Only One Source
Pricing
Firm Fixed Price
Place of performance
Durham, NC 27709, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00016 · Closeout. $0
Supplemental Agreement for work within scope P00015 · Make the transfer date of AS03 DEC 30 2022. $0
Other Administrative Action P00014 · Transfer remaining 50M lots to barda -$10,463,565
Supplemental Agreement for work within scope P00013 · Transfer remaining AS03 to barda stockpile $0
Supplemental Agreement for work within scope P00012 · The purpose of this modification is to suspend work and extend the delivery schedule for the delivery of the final 50M fill/finish doses. $0
Funding Only Action P00009 · The purpose of this modification is to DE-obligate funding attached to clin 0004 in order to correct an incorrect LOA -$4,055,756
Supplemental Agreement for work within scope P00008 · The purpose of this modification is to update the contract administrator. $0
Supplemental Agreement for work within scope P00007 · The purpose of this modification is to update the delivery schedule for the fill finish. $0
Other Administrative Action P00006 · The purpose of this modification is to update the wawf clause with the correct acceptor dodaac. $0
Supplemental Agreement for work within scope P00005 · The purpose of this modification is to update contract administrator. $0
Supplemental Agreement for work within scope P00004 · The purpose of this modification is to suspend the filing of 50M does of cgmp adjuvant. $0
Supplemental Agreement for work within scope P00003 · The purpose of this modification is to incorporate additional inscope work associated with packaging a security requirements. $4,055,756
Supplemental Agreement for work within scope P00002 · Update cdrl, delivery information and key personnel $0
Other Administrative Action P00001 · Administrative MOD to fix payment office. $0
Original award $342,000,000
Show all 15

About this award

Written by GovTribe AI ·

Glaxosmithkline, LLC, doing business as Glaxosmithkline, has been awarded a definitive contract by the Department of the Army to provide GLAXOSMITHKLINE ADJUVANT AS03. Valued at approximately $335.6 million, this firm fixed price contract runs from July 30, 2020 through December 30, 2022 and will be performed in Research Triangle Park, North Carolina. Under the contract, Glaxosmithkline will deliver its GLAXOSMITHKLINE ADJUVANT AS03 product to the Department of the Army in support of the agency's medical research and vaccine development programs. No major subcontractors or set aside designations were indicated.

Quick answers

Who was awarded contract W15QKN20C0048?

W15QKN20C0048 was awarded to Glaxosmithkline, LLC by ACC Picatinny (Army Contracting Command) on July 30, 2020.

How much is contract W15QKN20C0048 worth?

The government has obligated $331,536,435 on W15QKN20C0048. Its current value, with exercised options, is $335,592,191.

Which agency awarded contract W15QKN20C0048?

ACC Picatinny (Army Contracting Command) awarded W15QKN20C0048, with funding from Department of the Army (Department of Defense).

Was contract W15QKN20C0048 competed?

The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login